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1. Introduction 
In a certain way, drug developers are like the blind men in the well-known tale of “THE 
BLIND MEN AND THE ELEPHANT”, who believe the elephant to be like a water spout, a 
fan a pillar and a throne since they can only feel a different part but only one part of the 
elephant’s body such as trunk, ear, leg, back. Impossible to test a drug lead on human 
beings, drug developers also are obliged to forge a whole picture of the “elephant” – how a 
drug candidate would behave in a whole human body, by using information from the 
“parts” - models. The task of the drug developers are far more complex and challenging 
than the blind men, instead of touching only the surface, they have to go deep into the 
human bodies: organs, tissues, cells, genes, proteins, lipids, hormones … Furthermore, a 
living human being is a dynamic and interacting system, in a certain sense, the situation of 
the drug developers are even worse than the blind men: the blind men touch and feel a real 
elephant, the information that they get is true; a drug developer, most of the time, works on 
models, animal models or in vitro cell models, which are far from representing a human 
beings as a whole. As consequences, the information that one gets sometimes could be 
misleading. For drug developers, the misleading information could have serious 
consequences in terms of costs and human lives. 
This blind men’s approach may explain why a drug candidate, even though successfully 
passed pre-clinical stages, eventually failed at clinical trials. The failure of Torcetrapib, a 
drug developed by Pfizer, gives an example of just how difficult to develop a drug. 
Torcetrapib, designed to prevent heart attacks and strokes, is a cholesteryl-ester transfer 
protein (CETP) inhibitor. Genetic studies of the Japanese populations revealed that people 
with a deficiency of CETP presented a favorable lipid profile compared with unaffected 
family members: namely more High Density Lipoproteins (HDL, good) and less Low 
Density Lipoproteins (LDL, bad) (Inazu et al., 1990; Koizumi et al., 1991). CETP naturally 
became a target of drug development. Preclinical studies of Torcetrapib on different animal 
models (mice, rabbits, etc) didn’t reveal any severe side effects (Tall et al., 2007). But, 
medication of Torcetrapib on human beings caused severe hypertension and an increased 
mortality; apparently there was no obvious beneficial effects on coronary heart disease. The 
development of Torcetrapib was halted at 2006. 
This example illustrates another difficulty in drug development: the genetic heterogeneity of 
the human populations. The knowledge obtained from one group of people may not be 
applicable to another group of people. Quite often, this truth has been neglected.  
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Furthermore, human body is a complex dynamic system, with interconnected networks, 
equilibrium, feedback, compensation, redundancy, etc…, the cause-effect relationship 
between the target and the patho-physiological condition is not linear. In the example of 
CETP, people with the genetic deficiency of CETP, despite of having a favorable lipid 
profile, also suffer from coronary heart disease (Hirano et al., 1995). 
Unfortunately, Torcetrapib is not an exception. According to a statistics, the failure rate at 
Phase III clinical trials is estimated to be 50% and only 12% of compounds entering into the 
human phase testing will eventually makes to the market place (Chuang & Stein, 2004).  
However, despite of these difficulties, efficient and safe drugs have been successfully 
developed. The huge increase of the life-span of human populations is the testimony of this 
success. 
The question now is how to improve the success rate of the drug development? In light of 
the above discussions, we could give a generally recommendations: 
1. If possible, use models as close as possible to human patho-physiology and disease 
conditions.  
2. Take into account of the genetic heterogeneity whenever possible during the preclinical 
studies. 
3. Simulate as realistically as possible the dynamic and complex nature of biological 
responses. 
The recent development of 3D human tissue models and the in silico models are some 
attempts to get closer to the human “reality”. In this article, authors try to give an overview 
of the different models for studying the respiratory diseases and for drug development. First 
of all, in order to develop efficient and safe drugs, it is crucial to understand the nature and 
the underlying cellular and molecular mechanisms of the pathogenesis of the disease that 
one would like to treat. In the following sections, we will describe several major respiratory 
diseases. 
2. Respiratory diseases 
Respiratory disease is a medical term that encompasses pathological conditions affecting the 
normal function of the respiratory systems, making the gas exchange impossible. 
Anatomically, the respiratory system is composed of upper respiratory tract, trachea, 
bronchi, bronchioles, alveoli, pleura and pleural cavity, and the nerves and muscles of 
breathing. During the breathing, the respiratory system constantly expose to external insults 
such as bacteria, virus, particles, gas, etc… making the respiratory system highly vulnerable 
to various diseases. Indeed, according to the WHO World Health Report 2000, the top five 
respiratory diseases account for 17.4% of all deaths and 13.3% of all Disability-Adjusted Life 
Years (DALYs). Lower respiratory tract infections, chronic obstructive pulmonary disease 
(COPD), tuberculosis and lung cancer are each among the leading 10 causes of death 
worldwide. There are urgent and unmet needs of better treatments for respiratory diseases. 
Respiratory diseases could be classified in various ways. In this article, we will classify them 
by the cause (etiology) of the disease. As such, the respiratory diseases can be divided into 
the following categories: 
 Inflammatory lung disease 
 Obstructive lung diseases 
 Respiratory tract infections 
 Respiratory tumors 
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 Pleural cavity diseases 
 Pulmonary vascular diseases 
We are going to limit our scope to the respiratory tract infections and inflammatory lung 
diseases. However, it is necessary to point out that one disease may be classified in several 
categories. For example, asthma is caused by airway inflammation; the consequence is the 
airway obstruction. Viral infection may also contribute to asthma exacerbation. The 
interplay of multi-factorial risks makes the drug development even more challenging.  
2.1 Respiratory tract infections 
Over 200 different viruses have been isolated in patients with respiratory tract infections. The 
most common virus is the rhinovirus. Other viruses include the coronavirus, parainfluenza 
virus, adenovirus, enterovirus, and respiratory syncytial virus (RSV) (Mäkelä et al., 1998). Up 
to 15% of acute pharyngitis cases may be caused by bacteria, commonly Group A 
streptococcus in Streptococcal pharyngitis ("Strep Throat") (Bisno, 2001).  Influenza (the flu) is 
a more severe systemic illness which typically involves the upper respiratory tract. 
During evolution, the viruses as well as bacteria co-evolve and adapt to their host, acquiring 
so-called tropism, namely the specificity of a given virus or bacterium for a cell type, tissue 
or species. The well known example is the influenza viruses. Certain strains of influenza A 
viruses such as H5N1 infect specifically one species: avian, pig, or human, etc... Thanks to 
this species barrier, the deadly avian H5N1 has not been able to cause “pandemics” within 
human populations.  
Even though there are several determinants of the viral tropism, the main molecular basis of 
the viral tropism is the specific cell surface receptor(s) for viral entry. A typical and well-
studied example is the receptors for influenza viruses (Fig.1. and Fig.2.). 
  
 
Fig. 1. Schematic representation of the interaction of Influenza virus and its receptors.On the 
apical surface of the airway epithelial cells, most of the membrane proteins are glycosylated 
on serine (O-glycan) or asparagine (N-glycan). The glycans are often have a sialic acid (sia) 
tail linked to galactose (gal), which serves as receptor for Influenza A viruses such as H1N1.  
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Fig. 2. Two types of linkages which plays an important role in viral tropism. Avian 
Influenza A viruses prefer 2-3 linkage, human Influenza A viruses, 2-6, porcine Influenza 
A viruses are adapted to both 2-3 and 2-6. In the human lung, there exists a particular 
distribution pattern of these two linkages: 2-6 linkage is present mainly on the airway 
epithelial surface lining the respiratory tracts, from the nose down to the bronchioles. In 
contrast, 2-3 linkage is located in the alveolar cavity mainly on the type-II cells.  
The receptor of influenza A virus is glycosylated-proteins with a terminal sialic acid linked 
to galactose. There exist two main types of linkages: SA-2-3-Gal and SA-2-6-Gal. It has 
been shown that the avian Influenza A viruses prefer 2-3 linkage, human Influenza A 
viruses, 2-6, porcine Influenza A viruses are adapted to both 2-3 and 2-6.  
What is interesting is the distribution of these two types of linkage in human airway 
epithelial cells. Using lectin probes specific for each type of linkages, the distribution of 
these two types of linkages has been studied in the human lungs (Shinya et al., 2006; Van 
Riel et al., 2006). It has been demonstrated that epithelial cells in the paranasal sinuses, the 
pharynx, the trachea, the bronchi as well as in the terminal and respiratory bronchioles, 
mainly express SA-2-6-Gal. In contrast, SA-2-3-Gal was found on non-ciliated cuboidal 
bronchiolar cells at the junction between the respiratory bronchiole and alveolus, and a 
substantial number of cells lining the alveolar wall also expressed this molecule. Moreover, 
the SA-2-3-Gal-positive alveolar cells also reacted to an antibody against surfactant protein 
A; this suggests that they were alveolar type-II cells (which express surfactant proteinA) 
(Shinya et al., 2006; Van Riel et al., 2006). 
Using similar approach, Varki and Varki confirmed these results. Moreover, they discovered 
that this distribution pattern seems to be unique of human lungs, it is even absent in the 
lung of great apes (Varki & Varki 2009).   
Since most of the bacteria infect the human respiratory tracts without entering into the cells, 
the tropism of bacteria is less evident. But, in certain physiological as well as pathological 
conditions, bacteria preferentially infect certain species or tissues. As example, in patients 
suffering from cystic fibrosis (the pathology will be discussed below), the respiratory tracts 
of the patients are chronically colonized by P. aeruginosa which can rarely be eradicated. This 
chronic infection provokes lung inflammation and lung injury, leading to respiratory failure 
and death (Kerem et al., 1990). The reason of this persistent infection by P. aeruginosa is still 
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not clear. But it is reasonable to assume that the respiratory tracts of the CF patients provide 
a niche particularly favorable to P. aeruginosa. 
So, given these particular and unique pathogen and host relationship, it is preferable to use 
human models for drug development for treating viral and bacterial infections of the human 
respiratory tracts.  
2.2 Inflammatory lung diseases 
Another category of respiratory diseases is the inflammatory lung diseases such as asthma, 
cystic fibrosis, emphysema, chronic obstructive pulmonary, characterized by a high 
neutrophil count. The mechanisms of immune responses in cystic fibrosis, asthma, COPD 
diseases have been extensively documented. The common feature of these inflammatory 
airway diseases is the involvement of the respiratory airway epithelia. 
Cystic fibrosis (CF) is an autosomal recessive, a multisystem disorder, characterized 
primarily by defective electrolyte transport in epithelial cells and abnormally viscid mucus 
secretions from glands and mucus epithelia. The impairment of the mucociliary clearance 
leads to chronic infection and inflammation, ultimately causing cystic bronchiectasis, severe 
airflow obstruction and death (Boucher, 2004, 2007) (Figure 3). 
 
 
Fig. 3. Schema depicts normal airway epithelial ion transport, dysfunctional transport in 
CF.Normal airway epithelia (left): CFTR functions as a Cl- and it also regulates Na+ 
absorption (it inhibits ENaC). The quantity of NaCl on airway surface is optimally regulated 
to osmotically hydrate the periciliary and mucus layers allowing efficient mucus clearance. 
CF airway epithelia (right): In the absence of the CFTR protein in the apical membrane 
consequent to common CF mutations, such as ∆F508 CFTR, the CF epithelium can exhibit 
unrestrained Na+ absorption and a failure to secrete Cl-. These combined defects reduce the 
quantity of NaCl on CF airway surfaces, maintain less water osmotically on CF airway 
surfaces and, hence, lead to depletion of water in the periciliary liquid layer (PCL) and 
collapse of a thickened mucus layer onto the epithelial surface.  
Asthma is an inflammatory disease characterized by allergic reaction to allergens and 
chemicals. The hallmark of asthma diseases is the antigen-specific IgE production. Even 
though the effector cells in asthma pathogenesis are immune cells like dendritic cells, helper 
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T cells (usually CD4+ cells), eosinophils, neutrophils, etc… the airway epithelia play an 
important role in the induction phase of asthma. Indeed, recent advances suggest that a 
cytokine named Thymic Stromal Lymphopoietin (TSLP) might play a key role in biasing the 
Th0 cells to Th2 differentiation pathway (Rochman et al., 2008; Ziegler et al., 2006; Esnault et 
al., 2008; Shi et al., 2008). What is more, TSLPR-knock-out mice failed to develop lung 
inflammation upon ovalbumin challenge (Al-Shami et al., 2005). Conversely, the over-
expression of TSLP in mice induces spontaneous airway inflammation and atopic dermatis 
(Zhou et al., 2005; Yoo et al., 2005), suggesting TSLP is an important factor necessary and 
sufficient for the initiation of allergic airway inflammation. The implication of TSLP in Th2 
response is further confirmed by studies of other allergic diseases such as the skin atopic 
dermatis (Zhou et al., 2005) and intestinal immune homeostasis (Zaph et al., 2007). 
Interestingly, expression of TSLP is elevated in the bronchial biopsies from the asthmatic 
patients compared to that of healthy donors (Ying et al., 2005). 
Chronic Obstructive Pulmonary Disease (COPD) is now the fifth leading cause of death 
worldwide (Pauwels & Rabe, 2004) and it will become, as predicted by the World Health 
Organization (WHO), the third leading cause of death worldwide by 2030 
(www.who.int/respiratory/copd/en/index.html). Even though airborne pollutants such as 
smoke from the burning fuel or coals can cause COPD, the main inducing factor is the 
cigarette smoke. COPD is a complex syndrome comprised of airway inflammation, 
mucociliary dysfunction and consequent airway structural destruction. This process is 
considered non-reversible.  
Upon the irritant challenge, the airway epithelial cells synthesize and release pro-
inflammatory cytokines and chemokines such as IL-8, MIP-3, which in turn recruit 
neutrophils, CD8+ T-lymphocytes, B-Cells, macrophages and dendritic cells to the lumen of 
the airways. The matrix-metalloproteinases (MMP-6, MMP-9), among other mediators, 
cause airway injury and remodeling, eventually leading to airway obstruction.  
3. The Airway epithelium: Central to the pathogenesis of respiratory diseases 
From the above descriptions, it is clear that the airway epithelial cells occupy a central 
position in the pathogenesis of most respiratory diseases, ranging from infectious diseases, 
genetic diseases, to most inflammatory diseases. Indeed, it has been long recognized that the 
airway epithelium is more than just a barrier: it synthesizes and releases a large panel of 
chemokines, cytokines, lipids, growth factors, proteases, protease inhibitors, for example, IL-
8, Il-6, IL-17F, TGFs (Folkerts et al., 1998; Laberge et al., 2004; Suzuki et al., 2007). And the 
expression of these cytokines and chemokines are induced and modulated by various 
external insults like viral and bacterial infections, cigarette smokes (Nakamura et al., 2008) 
and are associated with disease conditions like CF, asthma, and COPD (Fig. 4). 
This paradigm provides a theoretic framework for developing more relevant in vitro cells 
models of allergic asthma and COPD, especially the in vitro 3D cell models of the human 
airway epithelium. 
4. The experimental models 
A survey of the existing models of respiratory diseases may be useful for the readers. 
Knowing the strengths and limitations of each model will help drug developers to choose 
the more appropriate tools for their work. 
www.intechopen.com
 The Use of In Vitro 3D Cell Models in Drug Development for Respiratory Diseases 175 
 
Fig. 4. The Airway epithelium - central to the pathogenesis of respiratory diseases. In 
addition to its barrier functions, the airway epithelium is also an immune-modulator 
involved in most of the respiratory diseases.   
4.1 Animal models 
Animal models are widely used for studying the respiratory diseases and for drug 
development. Due to the economical and technical reasons, the small rodents like mice and 
rats are the most popular and widely used animal models. Besides, chicken eggs, rabbits, 
guinea pig, cats, dogs, sheep, monkeys are also routinely used (Epstein, 2004). 
For example, embryonated chicken eggs have been extensively used for growing the 
influenza viruses and for vaccine production (Potkin & Potkin, 2006; Artenstein, 2009). 
However, since the dominant linkage in the embryonated chicken eggs is 2-3, some of the 
field strains grow poorly or not at all in chicken eggs. Furthermore, High mutation rates of 
RNA viruses like Influenza A allow the generation of viral escape mutants, rendering 
vaccines and drugs directed against virus encoded targets potentially ineffective (Neumann 
et al., 2009). A new strategy is to temporarily disable the host cellular factors necessary for 
viral replication, thus reduce the risk of selecting for resistant viral mutants. Using genome-
wide RNAi screen approach, Karlas et al. have identified hundreds of human host factors 
crucial for influenza A virus (H5N1) replication in A459 cells (Karlas et al., 2010). However, 
Due to the genetic drift of A549, a cancerous alveolar cell line, it is necessary to confirm 
these results in primary human pneumocytes. As discussed above, the major concern about 
pandemic threat of avian influenza A is the possibility of avian flu virus to acquire the 
ability to infect the upper human airway tracts which are rich in 2-6 linkage.  
As animal models, mice and rats are routinely used for studying respiratory diseases. 
Besides the economical considerations, the biggest advantage of rodent models is the 
possibility to modify genetically the animals. Indeed, transgenic mice with knock-out CFTR 
or with delta-F508 mutations have been created (Colledge et al., 1992; Snouwaert et al., 1992; 
Ratcliff et al., 1993; O’Neal et al., 1993; Hasty et al., 1995). Unfortunately, these transgenic 
mice don’t present lung problems as found in cystic fibrosis patients, highlighting once 
again the molecular, cellular and physiological differences between animals and human. 
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As for asthma and COPD animal models, since the rodents don’t naturally develop these 
human diseases, allergic asthma or COPD has to be induced artificially by immunizing and 
challenging the respiratory tracts with antigen/allergen or proteases/cigarette smokes (for 
reviews: Epstein, 2008; Churg et al., 2008). Even though some asthmatic symptoms like 
eosinophil infiltration, mucus hypersecretion, airway hyper responsiveness, and elevated 
IgE production, can be observed, the lung inflammation is often transient rather than 
chronic as in human being. Similarly, due to the considerable differences of lung anatomy 
and susceptibility to injurious agents among species (Bracke et al., 2007), none of the animal 
COPD models reproduces the exact changes seen in humans (Churg et al., 2008).  
Occasionally, naturally occurring animal disease models could also be found and used. 
For example, Ascaris suum-allergic sheep and flea-allergic dog have been discovered and 
used for studying asthma diseases and for drug development (Singh et al., 2002; Tang et 
al., 2003).  
One way to get closer to human disease conditions, so-called humanized animal models 
have also been made to explore the pathogenesis of allergic asthma: the human peripheral 
blood mononuclear cells were isolated and injected into T and B lymphocyte deficient 
severe combined immunodeficiency (SCID) mice, creating a human-SCID mouse. Even 
though it is an innovative approach, due to the complexity of the human immune systems, it 
is not possible to humanize all the immune cells of the SCID mouse.  
In short, animal models, even though useful, indispensable and informative, don’t give the 
true picture of the human respiratory diseases. Sometimes, it is even misleading. 
Furthermore, none of these animal models can reflect the human genetic heterogeneity 
which is key for developing safe and efficient drugs. 
4.2 Human respiratory disease models 
There are several categories of human disease models: 
 Cell lines 
 Primary cells 
 3D cell models 
 Cell co-cultures 
 Explants 
 In silico models 
Until now, the most popular human models are cell lines derived from various human 
tissues. 
4.2.1 Epithelial cell lines 
The airway epithelia constitute the first line of defense against the external insults. It has a 
pseudo-layer structure consisted of three main types of cells: ciliated epithelial cells, mucus 
cells and basal cells. The mucus cells synthesize and secret mucin-rich mucus which trap 
most of the inhaled particles, virus and bacteria, the later are eliminated from the body by 
muco-cilliary clearance via the cilia-beating. All the three cell types contribute to the 
pathogenesis of respiratory diseases, for example, inflammatory reaction, mucus 
hypersecretion, airway remodeling (Epstein, 2004; Verstraelen et al., 2008).  
As airway epithelial cell lines, the most frequently used ones are A549, BEAS-2B, Calu3, 
16HBE14o-, etc… The characteristics and uses of these cell lines have been nicely reviewed 
by Verstraelen et al., 2008. 
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A549 
Origin: This line was initiated in 1972 by D.J. Giard, et al. (Giard, 1972) through explant 
culture of lung carcinomatous tissue from a 58-year-old Caucasian male. As type II 
pulmonary epithelial cells (alveolar pneumocyte), it synthesizes lecithin with a high 
percentage of disaturated fatty acids (surfactants). It is oncogenic when tested in nude mice.  
Applications: The cells can be used to screen chemical and biological agents for ability to 
induce or affect differentiation and/or carcinogenesis. Mechanistic studies, pathway-
mapping and target-finding, or ranking of the toxicity potency of chemicals.  
BEAS-2B 
Origin: BEAS-2B cells were isolated from normal human bronchial epithelium obtained from 
autopsy of non-cancerous individuals. The cells were infected and immortalized with an 
adenovirus 12-SV40 virus hybrid Ad12SV40 and cloned. These cells retain the ability to 
undergo squamous differentiation in response to serum, and stained positively for keratins 
and SV40 T antigen. 
Applications: The cells can be used to test the toxicity of chemicals and biological agents 
relevant to upper airway epithelia. Suitable for mechanistic studies, pathway-mapping and 
target-finding. 
Calu-3  
Unlike most immortal cells, Calu-3 cells form sheets of cells that are welded to each other by 
tight junctions. These sheets form a fully functional epithelium that can transport large 
quantities of ions and fluid. In addition, Calu-3 cells have the highest level of natural CFTR 
expression of any known immortalized cell, even higher than some intestinal cell lines that 
once held the record. Thus, this cell line is suitable to study cystic fibrosis and drug 
discovery (Haws et al., 1994). 
4.2.2 Immune cells (Effector cells) 
Dendritic cells: Although both the skin and lung airway mucosa possess resident dendritic 
cells, the majority of studies conducted to date have utilized human peripheral blood 
mononuclear cell-derived dendritic cells (PBMC-DC) due to their relative ease of extraction 
and the ability to obtain larger quantities of cells (Casati et al., 2005). Several protocols have 
been established to generate human DC in vitro. Starting with blood or bone marrow-
derived CD34+ hematopoietic progenitor cells (HPC), DC can be generated under various 
culture conditions with a cocktail of specific cytokines. Despite of the progress made in the 
field, it is still difficult to obtain sufficient amount of primary DC cell for basic or clinic 
research. Therefore, the use of cell lines such as THP-1, KG-1, especially the MUTZ-3, proves 
to be invaluable (Santegoets et al., 2008). 
Mast cells, neutrophils, eosinophils, , basophils, are considered as effector cells which are 
involved in early and late phases of asthma by releasing a plethora of inflammatory 
mediators. Their roles in broncho-constriction, mucus secretion, and airway remodeling 
have clearly defined. Many therapeutics are targeting these effector cells and associated key 
molecules (Casale et al., 2008). These cells can be isolated from the blood or cord blood and 
cultured in vitro. Their behaviors such as migration, free radical production, viability and 
apoptosis, can be assessed after stimulation by allergen and cytokines (Frieri et al., 2003; 
Tang et al., 2003; Nilsson et al., 2004). 
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4.2.3 The drawbacks of cell lines 
1. These cells have been transformed by oncogenes one way or other, thus certain signal 
transduction networks have been deregulated.  
2. Genetic aberrations such as chromosomes loss, chromosomes translation, mutations, etc… 
3. These cell lines cannot give rise to fully differentiated phenotypes of the original tissues 
such as cilia formation, mucus secretion, epithelium repair and remodeling. 
4. Under the monolayer culture conditions, the cells behave totally different as they do in 
vivo situations.  These differences have been illustrated by comparing the responses of the 
same cancer cells to drugs (Bissell et al., 2006; Yamada et al., 2006; Griffith & Schartz, 2006). 
4.2.4 Fully differentiated 3D human airway epithelial models 
To overcome these shortcomings of the cell lines, different techniques have been developed 
to make 3 dimensional (3D) cultures, by providing a micro-environment or architecture 
closer to in vivo situations. Among these techniques, cellular matrix scaffold, hang-drop 
culture, perfusion culture chambers, air-liquid interface cultures, etc… 
However, in order to simulate the in vivo lung conditions, the ALI cultures seem to be more 
appropriate: the basal-lateral side of the epithelia is immerged in the culture medium and 
the apical side is exposed to humidified air with 5% CO2. Furthermore, with the Costar PET 
Transwell inserts, it is very practical and convenient to use. It is suitable for most of the 
applications, such as imaging, immune-cytochemistry, toxicity tests, electrophysiological 
studies (Ussing chamber measurement), assessment of drug permeation and drug 
formulations, etc… 
4.2.4.1 MucilAir 
It is a fully differentiated and ready-to-use 3D model of human airway epithelium, 
constituted with primary human epithelial cells freshly isolated from the nasal or bronchial 
biopsies. It is commercially available and ready-to-use (Epithelix, www.epithelix.com). 
MucilAir (Fig. 5.), is not only morphologically and functionally differentiated, but also can 
also be maintained in a homeostatic state for a long period of time. Using cells from diseased 
donors, different versions of MucilAir can be made such as asthmatic, allergic, COPD, CF, 
etc…  
4.2.4.2 Applications of MucilAir in drug development 
Due to its fully differentiated nature, MucilAir can be used for studying various respiratory 
diseases. In the following paragraphs, we will give some examples about the applications of 
MucilAir in drug development.  
4.2.4.2.1 Viral infections  
MucilAir has been successfully used for studying Pandemic H1N1 2009 influenza virus 
(Brookes et al., 2010). It is also suitable for other respiratory viruses like Respiratory 
syncytial virus (RSV) and Human Rhinovirus (HRV) (Fig. 6.). The results are highly 
reproducible.  
4.2.4.2.2 Electro-physiology of the airway epithelia (Ussing chamber measurements) 
One of the characteristics of the airway epithelia is the active ion transport which is essential 
for regulating and maintaining the ion composition and height of the pericilliary liquid 
layer. The ion channel activities of the airway epithelia can be monitored in a modified 
Ussing Chamber. In the following figure, the short circuit current mediated by CFTR is 
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absent when stimulated with Isoproterenol which increases the intra-cellular cyclic AMP 
(see above discussion on CF pathology). Typical recording is shown in Fig. 7.. Related to 
electrophysiology is the muco-ciliary clearance. It is convenient to use MucilAir for 
evaluating the drug effects on cilia beating and muco-ciliary clearance. 
 
 
Fig. 5. MucilAir, a fully differentiated 3D in vitro cell model of the human airway epithelia 
Epithelial cells were freshly isolated from the biopsies (nose, trachea, and bronchi), then 
seeded onto a semi-porous membrane (Costar Transwell, pore size 0.4 µm). After about 45 
days of culture at air-liquid interface, the epithelia were fully differentiated, both 
morphologically and functionally. Depending on the pathology of the donors, different 
versions of MucilAir could be made.  
 
 
Fig. 6. MucilAir was infected apically: A/WSN/33, H1N1 influenza, 1MOI; RSV A2, 
0.1MOI; HRV16, 1MOI. The virions were collected by washing the apical surface with 500 µl 
culture medium. The titre of the viruses was measured by ELISA.  
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Fig. 7. Measurement of the short-circuit current in modified Ussing chambers. The 
reconstituted epithelia are placed in modified Ussing chambers and the short-circuit 
currents are measured after the addition of various blockers and activators of the ionic 
channels. Addition of Amiloride (blocker of the sodium channels) reduced the current. The 
addition of Isoproterenol increased the current in normal MucilAir, but in MucilAir-CF. The 
addition of glybenclamide (an inhibitor of CFTR channel) completely inhibited the currents 
mediated by CFTR in normal MucilAir. 
4.2.4.2.3 Mucociliary clearance analysis 
The muco-ciliary clearance is the principal defense mechanism of the respiratory systems. 
The impairment of this function is the major cause of chronic infection and inflammation, as 
exemplified in cystic fibrosis disease. For experimental reasons, direct measurements of 
mucus velocity in human lungs are presently available only for the trachea, with values 
ranged from 4-6 mm/min. (Hofmann et al., 2002). The only reported value of the mucus 
velocity in the main bronchi is about 2.4 mm/min (Foster et al., 1982). Interestingly, the 
same value has been obtained by using an in vitro culture model of the bronchial airway 
epithelial cells (Masui et al., 1998). However, the velocity of muco-ciliary clearance varies 
considerable depending on individuals, anatomical location, and disease conditions, etc… 
Indeed, the values that we obtained from the nasal epithelia are slightly inferior to that of 
bronchial ones, about 1.8 mm/min (Fig. 8.). Due to the simplicity of in vitro methods, it is 
possible to access the drug effects on muco-ciliary clearance in various disease settings.   
4.2.4.2.4 Multi-endpoint test strategy  
In addition to its applications in viral infection and cystic fibrosis, MucilAir can also be used 
for testing the toxicity and efficacy of the drugs candidates. To this end, a multi-endpoint 
strategy is used (Fig. 9.). The drug candidates can be applied on the apical surface as liquids, 
solids, gaz, smoke and nanoparticles. The effects of drugs can be monitored by several 
endpoints: such as the trans-epithelial electric resistance (TEER), cell viability tests 
(Resazurin, LDH), cilia beating frequency monitoring, muco-ciliary clearance, mucus 
secretion, release of cytokines/chemokines.  
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Fig. 8. Due to its fully differentiated nature, muco-ciliary clearance can be easily studied in 
vitro on MucilAir. Briefly, the mucociliary clearance is monitored using a fully automated 
setup dedicated to video-microscopy. Microbeads of 5 microns are seeded onto the apical 
surface of MucilAir-normal or MucilAir-CF cultures. Then, pictures are taken every second 
during 1 minute in order to reconstitute movies showing the movement of the small 
particles. The particle movement is then tracked using dedicated software for calculating 
velocities of beads’ movement.  
 
 
Fig. 9. Multiple end points testing strategy for toxicity testing using MucilAir 
4.2.4.2.5 Dextran application 
One of the problems that drug developers frequently encounter is the solubility of the 
compounds: not all the chemicals are soluble or stable in solutions. It is also difficult to test 
powders or nanoparticles. In order to solve this problem, a procedure which allows testing 
all kinds of solid substances was developed (PCT/IB2010/053956). The idea is to use inert 
and neutral substances as carrier. Dextran was successfully used as carrier to deliver the 
insoluble chemical compounds and nanoparticles onto the apical surfaces of MucilAir. 
Dextran is a bacterial byproduct; the dextran macromolecule consists of glycan groups 
linked end to end. It didn’t show any harmful effect on MucilAir. The following figure 
describes the procedure and application of the dextran tablets (Fig. 10.).  
4.2.4.2.6 Simulation of chronic airway inflammation 
Airway epithelium is more than just a barrier; it is also an immune-modulator. Upon 
external stimulations, it synthesizes and releases a large panel of chemokines, cytokines, 
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lipids, growth factors, proteases, protease inhibitors. In the following figure (Fig. 11.), the 
epithelia were repetitively stimulated by Cytomix (TNF-α/LPS).  It is remarkable that the 
airway epithelial cells could recover after repetitive challenge of Cytomix, a relatively 
physiological stimulus. It was not the cases with some chemical compounds (data not 
shown). 
 
 
Fig. 10. Preparation and application of the Dextran Tablets  
 
 
Fig. 11. Inflammatory response of the epithelia. Before the stimulation, the basal level of IL-8 
was about 10 ng/ml. After 24 hours of stimulation with pro-inflammatory mediators 
(Cytomix = TNF- + LPS), the amount of IL-8 released was increased five-fold. Upon 
removal of the stimulus, the amount of IL-8 returned to basal level as day 0. The epithelia 
could respond to the stimulus in a physiological manner again and again. 
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4.2.4.2.7 Repeated dose and long term toxicity testing using MucilAir 
Quite often, it is necessary to perform repeated dose and Long term toxicity/efficacy test of 
drug candidates. Up to now, this kind of experiments can be performed only on animals. In 
the following graph, we provide a proof-of-concept for repeated dose tests using an in vitro 
cell model. It is a transposition of the OECD412 guideline for 28 day test on rodents. The 
TEER was used as endpoint, which is an indicator of the epithelial integrity (Fig. 12.). This is 
a very sensitive endpoint. The “No Observed Adverse Effect Level“(NOAEL) can be 
determined (around 10 mM). 
 
 
Fig. 12. Repeated dose tests of formaldehyde on MucilAir (28 days repeated dose exposure 
study). 6 hours per day exposure on MucilAir to Formaldehyde for a period of 28 days. 
Every day, tissue Integrity (TEER) were measured (N=3) then epithelia were reused for the 
next exposure.  
4.2.4.2.8 Drug permeation 
In recent decades, the nasal mucosa has become an established administration site for 
systemic as well as local drug delivery (Ugwoke et al., 2005).  For developing novel drugs 
intended for this route, reliable methods are needed for assessing the rate and extent of 
absorption across the nasal epithelium. Desired methods should enable studies of enhancer 
effects and toxicology. By transposing the Caco-2 protocol (Hubatsch et al., 2007) to 
MucilAir™, trans-epithelial permeability of drug candidates or xenobiotics can be assessed 
on MucilAir™. Since epithelium is grown on separable inserts, kinetic studies are facilitated 
(Fig. 13.). The results obtained are very similar using different batches of MucilAir™ derived 
from different donors. Apical to basolateral and basolateral to apical permeability studies on 
height reference compound were performed (Table 1).  
4.2.4.2.9 The problem of variability 
One of the concerns of using the primary human cells is the variability from donor to donor: 
researchers don’t like variability! Indeed, one of the gold standards of scientific analysis is 
the reproducibility. If one performs an experiment with a standard operating protocol, one 
should get the same results. We agree with this principle. But, the genetic heterogeneity of 
the human population is a reality that drug developers have to face sooner or later:  Exposed 
to the same allergens, only a small percent of people develop asthma. Not all the smokers 
www.intechopen.com
 Drug Discovery and Development – Present and Future 184 
suffer from COPD. This reality has to be taken into account whenever possible, and as early 
as possible. Thus, in our opinion, the donor-dependent variation is not a problem; on the 
contrary, it could be a solution for reducing failure rate at later stages. Using a large 
collection of frozen primary airway epithelial cells, it is possible to address the issue of the 
genetic heterogeneity of the human populations. With tools like genomics, proteomics, bio-
informatics, etc, it would be possible to pin down cellular and molecular mechanisms 
underlying the donor to donor variability.  
 
 
Fig. 13. Time course of the rate of permeability of Tripolidine.HCl from the apical to 
basolateral side (N=3). 
 
 
Table 1. Evaluation of transport of 8 reference compounds across MucilAir (N=3) 
Molecules Papp (cm/s) 
A→B
Papp (cm/s) 
B→A
Asymmetry
Ratio
Salicilic
Acid
7.7 x 10-5 1.7 x 10-5 0.2
Nicotine 2.1 x 10-5 3.3 x 10-5 1.6
Propranolol.
HCl
1.2 x 10-5 1.6 x 10-5 1.3
Ibuprofen 1.1 x 10-5 1.9 x 10-5 1.7
Tripolidine.
HCl
9.7 x 10-6 1.2 x 10-5 1.2
Tetracaïne.
HCl
8.0 x 10-6 1.1 x 10-5 1.3
Dopamine.
HCl
3.0 x 10-6 2.5 x 10-6 0.8
Atenolol 2.2 x 10-6 6.7 x 10-6 3.0
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4.2.5 Immune competent 3D models 
Despite the central rule of the airway epithelia, other cellular components are also 
implicated and necessary for understanding the pathology of respiratory diseases, especially 
the immune cells. 
Co-culture systems: To study the cross-talks between different types of cells, the simplest 
way is by co-culturing different cells involved in vitro. Such experiments have been carried 
out using established cell lines: for examples, BEAS-2B are co-cultured with human lung 
fibroblasts (HFL-1 or WISTAR-38) (Lang et al., 1998), human umbilical vein endothelial cells 
(ECV304) (Mögel et al., 1998), or eosinophils (Wong et al., 2005), and primary human BECs 
with alveolar macrophages (Ishii et al., 2005). Using 3D cell models like MucilAir™ and 
freshly isolated immune cells, more reliable and faithful co-culture systems could be 
developed for studying the inflammatory respiratory diseases like asthma or COPD diseases 
and for drug development. 
Explants: Another way is to use explants. In other words, part of animal or human lung was 
excised and cultured in vitro for a period of days or weeks. The effects of cytokines or 
chemical compounds on bronco-constriction have been studied (Wohlsen et al., 2003). Using 
explants models it is possible to assess immunomodulatory effects (Tan et al., 2009) and 
understand signaling processes involved in tissue hyperresponsiveness related to asthma 
(Morin et al., 2005). Precision Cut Lung Slides (PCLS) are now used for studying the effects 
of sensitizers. PCLS mirrors the complex interplay of different cell types in the living organ 
and allows physiological processes to be mimicked (Henjakovic et al., 2008). The problem 
with the lung explants is the rapid degradation of the tissue slices. It is also difficult to 
obtain health, normal tissues. 
Lung on a chip: Ideal is to reconstitute the lung on a chip. Some attempts have been made. 
For example, Ingber’s lab designed and constructed a microfluidics system, so-called Lung 
on a chip that reproduces both the lung’s alveolar-capillary interface and the mechanical 
effects of breathing on that interface—all on a polymer chip about 2 cm long (Huh et al., 
2010). Another example is a so-called Multi-Compartmental Bioreactor designed on the 
basis of allometric scaling laws in order to recreate physiological life conditions of four 
different human cell types (pancreatic, adipocyte, endothelial and hepatic cells), 
interconnected each other through media flow (Vozzi et al., 2011). Some physiologically 
relevant results have been obtained by Vozzi and coworkers, suggesting that interactions, 
mediated by metabolites present in media flow, have a remarkable effect more than the 
physical interaction and can lead to a restoration of physiological cell life conditions.  
By incorporating the immune cells into these microfluidics systems, it is possible to build an 
immune-competent human in vitro lung model for studying the inflammatory respiratory 
diseases like asthma and COPD. 
4.3 In silico models: A systems biological approach - virtual cells, virtual organs, and 
virtual patients 
Despite the spectacular successes of molecular biology, some scientists did feel the 
drawbacks of the “blind men’s approach”, and they tried to take a more holistic viewpoint 
to describe the biological systems (von Bertalanffy, 1968; Noble, 2006).  Back to 1960, Noble 
already developed the first computer model of the heart pacemaker (Noble, 1960).  From 
2000 onward, so-called systems biology has been gaining popularity and importance. The 
systems biology tries to put the parts - head, ear, trunk, and legs -  together to form a whole 
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elephant: namely to achieve a holistic, quantitative, and predictive understanding through 
mathematical models that enable an iterative cycle between prediction and experiments 
(Sauer et al., 2007). Based on systemwide component identification and quantification 
(“omics” data) at the level of mRNA, proteins, and small molecular weight metabolites, Ishii 
et al. made a “virtual cell” which includes both the constituting components and the 
functional state of a metabolic network, providing a proof-of-concept for integrating a 
heterogeneous data set into a coherent whole (Ishii et al., 2007). 
With increasing calculation capacity and better software, it is now possible to simulate more 
realistically the biological processes at all levels: molecular interaction (ligand-receptor), 
virtual cells, virtual organs, and even virtual patients (Epstein et al., 2004). The in silico 
approach allows to rapidly integrating new data and novel knowledge, and it can get better 
and better with time. It is reasonable to hope that in the near future, based on systemwide 
data collection using relevant human 3D cell/tissue models, we could build a virtual lung 
for studying the respiratory diseases and for new drug development. 
5. Conclusion 
Each model has its strengths and weaknesses and there is no perfect respiratory disease 
model. Depending on the goal or on application, one model could be better than another. 
Since the drugs are to be used by human beings, it is logic to assess the toxicity and efficacy 
on cells of human origin, especially on 3D human models. Due to its central role in 
pathogenesis of respiratory diseases, the 3D in vitro cell models of the human airway 
epithelium deserve more attention in the future. We believe that the 3D cell models like 
MucilAir are highly relevant and valuable for development of new drugs.  
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relevant and robust tools, methods, models, and validated biomarkers that are predictive of clinical effects in
terms of diagnosis, prevention, therapy, and prognosis. There is a growing emphasis on translational
research, a bidirectional bench to the bedside approach, in an effort to improve the process efficiency and the
need for further innovations. The authors in the book discuss the current and evolving state of drug discovery
and development.
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